

# SYMPLIFY – assessing a multi-cancer early detection test in individuals referred with signs and symptoms of cancer

<b>Submission date</b> 24/06/2021	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 13/08/2021	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 17/10/2024	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Cancer is easier to treat if it is diagnosed early. The NHS has developed rapid referral pathways to allow cancers to be diagnosed earlier, but this requires us to run tests on a lot more people than turn out to have cancers. This creates worry for some people, may not be the most efficient use of NHS resources, a significant proportion of cancers are diagnosed via other routes, often when it is too late to cure them.

We know that the DNA from cancers can be detected in the blood early on and want to use this fact to detect cancers earlier than existing pathways. In this study we want to check the performance of one such multi-cancer early detection (MCED) test.

### Who can participate?

People sent to one of 5 rapid referral pathways by their GP because they have symptoms that might be due to cancer.

### What does the study involve?

People taking part in the study will have their diagnostic test(s) in the normal way, but will also give a blood sample and permission for us to check their health records later to see if they were diagnosed with cancer and what appointments and other tests they had.

At the end of the study, having tested the blood with the MCED test, we will understand more about how well it works in this group of people, and expect that this will help us to design another trial where we check how to use the test to decide who needs rapid referral to look for a possible cancer and what tests to use following a positive MCED result.

### What are the possible benefits and risks of participating?

If someone participates, they will be contributing to important research into how to detect cancer early. This may benefit people in the future. If the Galleri™ test turns out to detect cancer early, we may be able to treat more cancers more successfully.

We will do everything we can to make sure participants in this study don't experience any harm. They will need to give a blood sample. Although this process is generally safe, they may experience discomfort or light-headedness, and there is a small risk of infection. If blood needs

to be taken as part of their hospital care, the research blood sample will be taken at the same time.

Where is the study run from?  
University of Oxford (UK)

When is the study starting and how long is it expected to run for?  
February 2021 to November 2022

Who is funding the study?  
Grail Bio UK Ltd

Who is the main contact?  
Sarah Pearson, octo-symplify@oncology.ox.ac.uk

**Study website**  
<https://www.oncology.ox.ac.uk/>

## Contact information

**Type(s)**  
Public

**Contact name**  
Mrs Sarah Pearson

**ORCID ID**  
<http://orcid.org/0000-0001-5386-1953>

**Contact details**  
OCTO, Dept of Oncology  
University of Oxford  
Old Road Campus Research Building  
Old Road Campus  
Roosevelt Drive  
Oxford  
United Kingdom  
OX3 7DQ  
+44 (0)1865 227170  
octo-symplify@oncology.ox.ac.uk

## Additional identifiers

**EudraCT/CTIS number**  
Nil known

**IRAS number**  
299310

**ClinicalTrials.gov number**

Nil known

### **Secondary identifying numbers**

OCTO\_105, IRAS 299310, CPMS 49672

## **Study information**

### **Scientific Title**

SYMPLIFY – Observational study to assess a multi-cancer early detection test in individuals referred with signs and symptoms of cancer

### **Acronym**

SYMPLIFY

### **Study objectives**

To evaluate the performance of a multi-cancer early detection (MCED) test for the detection of invasive cancer and the identification of cancer signal origin

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Approved 22/06/2021, London Central REC (Barlow House, 3rd Floor, 4 Minshull Street, Manchester, M1 3DZ, UK; +44 (0)207 104 8225; londoncentral.rec@hra.nhs.uk), ref: 21/LO/0456)

### **Study design**

Prospective observational multi-centre cohort

### **Primary study design**

Observational

### **Secondary study design**

Cohort study

### **Study setting(s)**

Hospital

### **Study type(s)**

Diagnostic

### **Participant information sheet**

Not available in web format. Please use contact details to request a participant information sheet

### **Health condition(s) or problem(s) studied**

Early detection of cancer

### **Interventions**

Participants will be asked to give consent and provide a single blood sample during one visit to hospital. After that the participants have no further direct involvement, all follow-up is through

collection of data. We collect data on participants at 3 and 12 months from registration into the study to find out whether or not they had a diagnosis of cancer. (We will also do a check at 9 months to collect any data that was not available at the 3 month timepoint).

### **Intervention Type**

Other

### **Primary outcome measure**

At an interim analysis within 3 months of complete enrolment with complete analysis at 12 months of enrolment, measured by comparing blood sample analysis and patient notes:

1. Positive Predictive Value
2. Negative Predictive Value
3. Sensitivity
4. Specificity
5. Cancer signal origin accuracy

### **Secondary outcome measures**

At an interim analysis within 3 months of complete enrolment with complete analysis at 12 months of enrolment, measured by comparing blood sample analysis and patient notes:

1. Concordance between referral pathway selected by GP and CSOs identified by MCED
2. Number of true positives/number of patients referred within each referral pathway

### **Overall study start date**

01/02/2021

### **Completion date**

30/11/2022

## **Eligibility**

### **Key inclusion criteria**

1. Participants referred to an RDC or relevant 2WW pathway to rule a cancer diagnosis in or out will be invited to participate in the study.
2. Willing and able to give informed consent for participation in the study.
3. Male or Female, aged 18 years or above.
4. Referred to a RDC or a gynae, lung, upper GI or lower GI cancer 2WW pathway.

### **Participant type(s)**

Patient

### **Age group**

Adult

### **Lower age limit**

18 Years

### **Sex**

Both

### **Target number of participants**

6,000

**Total final enrolment**

6238

**Key exclusion criteria**

1. Has a history of invasive or haematological malignancy diagnosed within the previous 3 years.
2. Has undergone definitive treatment for invasive or haematological malignancy in the last 3 years (adjuvant hormone therapy is permissible in this context).
3. Is taking cytotoxic or demethylating agents such as methotrexate.
4. Previous or current participation in another GRAIL study. "Participation" is defined as having signed consent and provided a blood sample.

**Date of first enrolment**

05/07/2021

**Date of final enrolment**

30/11/2021

## **Locations**

**Countries of recruitment**

England

United Kingdom

Wales

**Study participating centre**

**Southampton General Hospital**

University of Southampton and University Hospital Southampton NHS Foundation Trust  
Tremona Road  
Southampton  
United Kingdom  
SO16 6YD

**Study participating centre**

**Buckinghamshire Healthcare NHS Trust**

Mandeville Road  
Aylesbury  
United Kingdom  
HP21 8AL

**Study participating centre**

**Churchill Hospital**

Oxford University Hospitals NHS Foundation Trust  
Old Road  
Headington  
Oxford  
United Kingdom  
OX3 7LE

**Study participating centre****Royal Berkshire Hospital**

Royal Berkshire NHS Foundation Trust  
London Road  
Reading  
United Kingdom  
RG1 5AN

**Study participating centre****Basildon and Thurrock University Hospital**

Mid and South Essex NHS Foundation Trust  
Nethermayne  
Basildon  
United Kingdom  
SS16 5NL

**Study participating centre****Torbay & South Devon Foundation Trust**

Torquay  
United Kingdom  
TQ2 7AA

**Study participating centre****Royal Cornwall Hospital**

Royal Cornwall Hospital NHS Trust  
Truro  
United Kingdom  
TR1 3HD

**Study participating centre****Royal Free Hospital**

Royal Free London NHS Foundation Trust  
Pond Street

London  
United Kingdom  
NW3 2QG

**Study participating centre**

**University College London Hospital**

University College London Hospitals NHS Foundation Trust  
250 Euston Road  
London  
United Kingdom  
NW1 2PG

**Study participating centre**

**North Middlesex University Hospital NHS Trust**

London  
United Kingdom  
N18 1QX

**Study participating centre**

**York Hospital**

York & Scarborough Teaching Hospitals NHS Foundation Trust  
York  
United Kingdom  
YO31 8HE

**Study participating centre**

**Hull University Teaching Hospitals NHS Trust**

Hull  
United Kingdom  
HU16 5JQ

**Study participating centre**

**Wales - multiple hospitals under one lead site (Velindre NHS Trust)**

Cardiff  
United Kingdom  
CF14 2TL

**Study participating centre**

**Chelsea and Westminster Hospital NHS Foundation Trust**  
Chelsea & Westminster Hospital  
369 Fulham Road  
London  
United Kingdom  
SW10 9NH

## **Sponsor information**

### **Organisation**

University of Oxford

### **Sponsor details**

Clinical Trial and Research Governance Team  
Joint Research Office  
1st floor, Boundary Brook House  
Churchill Drive  
Headington  
Oxford  
England  
United Kingdom  
OX3 7GB  
+44 (0)1865 616480  
ctrq@admin.ox.ac.uk

### **Sponsor type**

University/education

### **Website**

<http://www.ox.ac.uk/>

### **ROR**

<https://ror.org/052gg0110>

## **Funder(s)**

### **Funder type**

Industry

### **Funder Name**

Grail Bio UK Ltd



# Results and Publications

## Publication and dissemination plan

Planned publication in high-impact peer reviewed journal.

## Intention to publish date

30/06/2023

## Individual participant data (IPD) sharing plan

The current data sharing plans for this study are unknown and will be available at a later date

## IPD sharing plan summary

Data sharing statement to be made available at a later date

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		20/06/2023	26/06/2023	Yes	No
<a href="#">HRA research summary</a>			28/06/2023	No	No
<a href="#">Other publications</a>	A comparison of cancer data obtained on-site during SYMPLIFY with data from English and Welsh national cancer registries	09/10/2024	17/10/2024	Yes	No